tbuckley/cabot-search huggingface dataset:
Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy
Authors: Maria Gkotzamanidou, Masood A. Shammas, Evangelos Terpos, Enrique M. Ocio, Jesús F. San Miguel, Nikhil C. Munshi, Meletios A. Dimopoulos, Vassilis L. Souliotis
Journal: Blood (2013)
Chimerism Analysis after Haploidentical Stem Cell Transplantation: Is It Necessary for All Patients?
Authors: Faezeh Legrand, Valerio Maisano, Sabine Fürst, Angela Granata, Marie Joelle Mozziaconacci, Catherine Faucher, Claude Lemarie, Samia Harbi, Christophe Picard, Stephania Bramanti, Boris Calmels, Christian Chabannon, Raynier Devillier, Didier Blaise
Journal: Blood (2016)
VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial.
Authors: Jean Luc Harousseau, Claire Mathiot, Michel Attal, Gerald Marit, Denis Caillot, Mohamad M.M. Mohty, Cyrille Hullin, Thierry T.F. Facon, Iain I.W. Webb, Philippe Moreau
Journal: Blood (2007)
A Kinome shRNA Screen to Identify Pathways That Regulate Megakaryocyte Polyploidization and New Targets for Differentiation Therapy
Authors: Qiang Jeremy Wen, Serena Silver, Tim Lewis, Sridevi Ponduru, Vlado Dancik, Ben Goldenson, Mark Bray, Anne Carpenter, Paul Clemons, David Root, Andrew Stern, Robert Gould, John Crispino
Journal: Blood (2010)
A Single Center Experience with Allogeneic Sibling Umbilical-Cord-Blood Transplantation in Children with Malignant and Non-Malignant Disease.
Authors: Yongping Song, Yanli Zhang, Baijun Fang, Xudong Wei, Lulu Lu, Xinhu Zhu, Ping Wang, Yufu Li, Quanli Gao, Guiye Wang, Lugui Qiu, Chunhua Zhao
Journal: Blood (2005)
HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma
Authors: Roberta Zappasodi, Alessandra Cavanè, Monica Tortoreto, Cristina Tringali, Giusi Ruggiero, Lorenzo Castagnoli, Bruno Venerando, Nadia Zaffaroni, Serenella M Pupa, Alessandro Massimo Gianni, Massimo Di Nicola
Journal: Blood (2012)
Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome
Authors: Athena Kritharis, Jennifer A. Kanakry, Laurie H. Sehn, Tatyana Feldman, Aimee Kroll, Randy D. Gascoyne, Adam M. Petrich, Jeremy S. Abramson, Francisco Hernandez-Ilizaliturri, Zeina Al-Mansour, Camille Adeimy, Jessica Hemminger, Nancy L. Bartlett, Anthony R. Mato, Paolo Caimi, Ranjana Advani, Andreas K. Klein, Izidore S Lossos, Oliver W. Press, Sonali M. Smith, Jesus C Fabregas, Chadi Nabhan, Timothy S. Fenske, Jonathan W. Friedberg, Julie M. Vose, Kristie A. Blum, Andrew M. Evens
Journal: Blood (2014)
Cross-Presentation Is a Source of Tumor Antigens for Multiple Myeloma Immunotherapy
Authors: Alexander A. Perakis, Haley L. Peters, Jason Roszik, Mao Zhang, Anna Sergeeva, Celine Kerros, Pariya Sukhumalchandra, Anne V. Philips, Maria R. Khouri, Rahul U. Popat, Lisa St. John, Amjad Talukder, David H. Hawke, Greg Lizee, Elizabeth A. Mittendorf, Jeffrey J. Molldrem, Gheath Alatrash
Journal: Blood (2016)
Characterising a SOX2+ OLIG2+ glioma stem cell using Crispr-engineered fluorescent reporters in primary patient-derived GBM and DIPG cells.
Authors: Jack Finlay, Clement Hallou, Pooran Dewari, Steven Pollard, Manav Pathania, Harry Bulstrode, David Rowitch
Journal: Neuro-Oncology (2019)

Abstract Malignant glioma can be understood as a cancer stem cell disease. There is strong evidence that expression of a core set of neural stem cell master regulators is necessary and sufficient for tumour initiation in both adult and childhood disease subtypes, and across a range of underlying mutation signatures and expression profiles. We hypothesise that a double positive SOX2+ OLIG2+ progenitor is the cancer stem cell in H3K27M diffuse intrinsic pontine glioma (DIPG) and adult glioblastoma (GBM) alike. We present expression data in 4 patient-derived cell lines (2 adult GBM, 2 DIPG) in vitro and in a defined mutation mouse model of the H3K27M disease, demonstrating high expression levels of SOX2 and OLIG2 in serum-free culture and especially in the invasive tumour. We then demonstrate derivation of patient-derived human dual reporter lines, using a CRISPR targeting approach to add fluorescent reporters at the endogenous SOX2 and OLIG2 loci. With these tools, we aim to characterise the tumour-initiating potential of the SOX2+ OLIG2+ fraction. We further aim to identify cell surface markers whose expression is driven by this transcription program and which might represent targets for novel molecular therapies.
Abstract 14875: Reporting Quality of Studies Measuring Endothelial Dysfunction in Diet Intervention Studies
Authors: Rebecca Costello, Cynthia Lentino, Leila Saldanha, Mary Engler, Marguerite Engler, Pothur Srinivas, Christopher Sempos
Journal: Circulation (2013)

Vascular endothelial dysfunction (EF), most often measured by flow mediated dilation (FMD), has been studied as a surrogate marker for atherosclerosis and as an indicator of vascular health and rea...
FLT4 Expressing CD34+CD38- Leukemic Stem Cells in Bone Marrow of Refractory Patients are Protected by Receptor Internalization under Abundant VEGF-C Condition
Authors: Ji Yoon Lee, Sung-Eun Lee, A-Reum Han, Hee-Sun Hwang, Woo-Sung Min, Heeje Kim
Journal: Blood (2016)
A Naive NK Cell Repertoire in the Circulation of Haploidentical Stem Cell Donors Pre Mobilization Predicts Rejection of Cord Myeloid Cells in Patients Undergoing Combined Haploidentical and Unrelated Cord Blood HSCT
Authors: Mattias Carlsten, Robert N. Reger, Ritesh Kotecha, Enkhtsetseg Purev, Xin Tian, Roger Kurlander, Georg Aue, Richard W. Childs
Journal: Blood (2016)
The Human Specific microRNA-941 Is a Key Member of a microRNA Signature of Functionally Validated Leukemic Stem Cells from Patients with Acute Myeloid Leukemia
Authors: Susann Ihme, Medhanie A. Mulaw, Hartmut Döhner, Konstanze Döhner, Christian Buske, Michaela Feuring-Buske
Journal: Blood (2016)
TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors
Authors: Scott R. Solomon, Connie Sizemore, Xu Zhang, Stacey Brown, Katelin Connor, Lawrence E. Morris, H. Kent Holland, Asad Bashey
Journal: Blood (2014)
Abstract 14181: Computed Tomography-Derived Fractional Flow Reserve for the Prediction of Functional Ischemia
Authors: Tri M Trinh, Rine Nakanishi, Dong Li, Matthew J Budoff
Journal: Circulation (2017)

Objective: Fractional flow reserve by coronary computed tomography angiography (FFRCT) is a novel noninvasive method of assessing functional ischemia. There has not been any large comparison betwee...
Allogeneic Stem Cell Transplantation (SCT) with Non Myeloablative Conditioning Regimen (NST) Following Intensive Consolidation May Be Equivalent to Conventional alloSCT and Superior to autoSCT for Patients over 50 with Acute Myeloid Leukemia (AML) in 1stCR: First Results of the AML 2001 Trial.
Authors: B. Lioure, J. Delaunay, D. Blaise, N. Milpied, P. Guardiola, J.Y. Cahn, B. Witz, E. Jourdan, L. Legros, E. Randriamalala, M. Ojeda, C. Himberlin, Michel Attal
Journal: Blood (2006)
The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma
Authors: Mérédis Favreau, Eline Menu, Karin Vanderkerken, Sylvia Faict, Ken Maes, Els Van Valckenborgh, Elke De Bruyne, Srinath Govindarajan, Michael Drennan, Xavier Leleu, Lennart Zabeau, Jan Tavernier, Koen Venken, Dirk Elewaut
Journal: Blood (2016)
Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).
Authors: Xavier C. Badoux, Michael Keating, Susan O'Brien, Tapan Kadia, Alessandra Ferrajoli, Stefan Faderl, Charles Koller, Guillermo Garcia-Manero, Jan A. Burger, William G. Wierda
Journal: Blood (2009)
Impact of Refined Disease Risk Index after Single and Double Umbilical Cord Blood Transplantation in Adults with Hematological Malignancies
Authors: Annalisa Paviglianiti, Annalisa Ruggeri, Guillermo Sanz, Noel Milpied, Didier Blaise, Albert Esquirol, William Arcese, Christelle Ferra, Norbert Ifrah, Jean Henri Bouris, Kavita Raj, Joan Hendrik Veelken, Simona Sica, Nathalie Contentin, Adrian Bloor, Fernanda Volt, Chantal Kenzey, Vanderson Rocha, Eliane Gluckman
Journal: Blood (2016)
Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis
Authors: Neeraj Saini, Junsheng Ma, Denái R. Milton, Romil Patel, Ankur Varma, Qaiser Bashir, Ruby Delgado, Akash Mukherjee, Gabriela Rondon, Uday R. Popat, Chitra M. Hosing, Yago Nieto, Partow Kebriaei, Amin M. Alousi, Sairah Ahmed, Guilin Tang, Rohtesh Mehta, Samer Srour, Issa F. Khouri, Swaminathan Iyer, Donna M. Weber, Sheeba K. Thomas, Hans C. Lee, Elisabet E. Manasanch, Krina K. Patel, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash
Journal: Clinical Cancer Research (2019)

Patients with multiple myeloma with t(11;14) have been considered to have standard-risk disease. However, several recent reports have shown contradictory results. We identified 95 patients with multiple myeloma with t(11;14) on FISH studies, who underwent upfront autologous hematopoietic stem cell transplant (auto-HCT) at our center. We compared their outcome with a group of standard-risk patients with multiple myeloma who had diploid cytogenetics by both conventional cytogenetics (CC) and FISH (n = 287).To reduce the bias between the groups, we performed a 1:1 propensity score matching technique for analysis. A total of 160 patients, 80 in each group, were identified. Patients in the 2 groups were matched for age, International staging system stage at diagnosis, serum creatinine at presentation, disease status at auto-HCT, type of preparative regimens, dose of melphalan used for conditioning, and induction and maintenance regimens.Patients in t(11;14) group had a post auto-HCT overall response rate (ORR) of 97.5% (78/80), compared with 100% (80/80) in the standard-risk control group (P = 0.50). Complete response rate in the t(11;14) group was 35% (28/80), compared with 45% (36/80) in the standard-risk control group (P = 0.26). The 4-year PFS rates were 40.8% (95% CI, 29.6%-56.1%) and 51.1% (95% CI, 39.4%-66.3%) in the t(11;14) and standard-risk control groups, respectively (P = 0.14). The 4-year OS rates were 74.9% (95% CI, 63.3%-88.7%) and 88.3% (95% CI, 80.4%-97.0%) in the t(11;14) and standard-risk control groups, respectively (P = 0.17). Also, patients with t(11;14) with concurrent cytogenetics had significantly poor PFS and OS compared with a propensity matched standard-risk control group.Our study confirms that t(11;14) multiple myeloma undergoing upfront autologous transplantation had similar outcomes as patients with multiple myeloma with normal cytogenetic and FISH studies. Existence of additional genomic aberrations by CC or FISH was associated with a worse outcome.
An Autosomal-Recessive GFI1B Mutation Defines the Splice Isoform p37 As Essential for Biogenesis of Functional Human Platelets, but Dispensable for Erythropoiesis
Authors: Harald Schulze, Axel Schlagenhauf, Georgi Manukjan, Christine Beham-Schmid, Oliver Andres, Eva Klopocki, Eva-Maria König, Harald Haidl, Simon Panzer, Karina Althaus, Wolfgang Muntean, Wolfgang Schwinger, Christian E. Urban, Andreas Greinacher, Tamam Bakchoul, Markus Seidel
Journal: Blood (2016)
Development of a Genetic Tool Based on BCR-ABL Transgenic Drosophila Melanogaster for Identification of Genes Involved in CML Progression and Drug Testing.
Authors: Daniela Cilloni, Francesca Messa, Francesca Arruga, Enrico Bracco, Paolo Nicoli, Emanuela Messa, Stefano Ulisciani, Ilaria Iacobucci, Giovanni Martinelli, Thea Kalebic, Michele Baccarani, Fabian Feiguin, Giuseppe Saglio
Journal: Blood (2007)
The Significance and Optimal Number of Cycles of HD-AraC Consolidation Chemotherapy for Non-CBF AML
Authors: Yosuke Nagahata, Yoshimitsu Shimomura, Yotaro Ochi, Yusuke Koba, Yasuhiro Kazuma, Nobuhiko Yamauchi, Yuichiro Ono, Nobuhiro Hiramoto, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Takayuki Ishikawa
Journal: Blood (2014)
Incidence and Clinical Features of Calreticulin mutation in Patients with Jak2V617F-Negative Essential Thrombocytosis and Primary Myelofibrosis from Singapore
Authors: Chin-Hin Ng, Christopher W.S Ng, Bingwen Eugene Fan, Kiat-Hoe Ong, Elaine Seah, Huijun Zhou, Siew-Chuan Evelyn Koay, Wee-Joo Chng
Journal: Blood (2014)
Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches
Authors: Tatjana Bilich, Annika Nelde, Daniel J. Kowalewski, Janet Peper, Mirle Schemionek, Lothar Kanz, Helmut R. Salih, Tim H. Brümmendorf, Vladan Vucinic, Dietger Niederwieser, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S. Stickel
Journal: Blood (2016)
BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS
Authors: Petra Gorombei, Beurlet Stephanie, Nader Omidvar, Krief Patricia, Le Pogam Carole, Pierre de la Grange, Leboeuf Christophe, Anne Janin, Noguera Maria-Elena, Marina Konopleva, Michael Andreeff, Pla Marika, West Robert, Pierre Fenaux, Christine Chomienne, Rose Ann Padua
Journal: Blood (2012)
Inhibition of Phosphorylation of ERK in CLL Cells Pre-Treatment Correlates Best with Response to Dasatinib, Fludarabine, and Rituximab for Patients with Relapsed CLL
Authors: Philip C. Amrein, Xin Kai, Yasuyuki Iuchi, Jon Arnason, Jennifer R. Brown, Karen K. Ballen, Eyal C. Attar, Amir T Fathi, Ephraim P. Hochberg, HyukJoo Hwang, Shiv Pillai
Journal: Blood (2014)
Phase 2 Trial of the Histone Deacetylase Inhibitor Valproic Acid as a Monotherapy or in Combination with All-Trans Retinoic Acid in 24 Patients with Acute Myeloid Leukemia.
Authors: Andrea Kuendgen, Corinna Strupp, Barbara Hildebrandt, Sabine Knipp, Baerbel Junge, Rainer Haas, Ulrich Germing, Norbert Gattermann
Journal: Blood (2004)
Prognosis of Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction
Authors: Avraham Frisch, Ronit Leiba, Chezi Ganzel, Tsila Zuckerman, Nuhad Haddad, Riva Fineman, Yishai Ofran
Journal: Blood (2016)
Reprogramming Aberrant B Cell-Subsets to Improve Immune Function in Multiple Myeloma
Authors: Rao H. Prabhala, Andreea Negroiu, Saem Lee, Mariateresa Fulciniti, Puru Nanjappa, Harsha K. Prabhala, Adithya Munshi, Irene M. Ghobrial, Paul G. Richardson, Jacob Laubach, John Daley, Steven P. Treon, Charles Allam, Kenneth C. Anderson, Nikhil C Munshi
Journal: Blood (2012)
CD64 Expression Is An Independent Adverse Prognostic Factor in Pediatric Acute Myeloid Leukemia Treated with Allogeneic Stem Cell Transplantation,
Authors: Maher Albitar, Amal Alseraihy, Mouhab Ayas, Abdullah Al-Jefri, Ali Al-Ahmari, Asim F Belgaumi, Claudia Ulrike Walter, Randa Nounou, Salem Khalil, Nasir Bakshi, Tarek Owaidah, Hassan El-Solh
Journal: Blood (2011)
Expression of FAK and Its Involvement in the Progression of B-Cell Chronic Lymphocytic Leukemia
Authors: Cristina Gattazzo, Andrea Visentin, Alberto Pavan, Veronica Martini, Federica Frezzato, Valentina Trimarco, Severin Filippo, Chiodin Giorgia, Francesca Dattoma, Monica Facco, Gianpietro Semenzato, Livio Trentin
Journal: Blood (2014)
Selenium and outcome in heart failure
Authors: Nils Bomer, Niels Grote Beverborg, Martijn F. Hoes, Koen W. Streng, Mathilde Vermeer, Martin M. Dokter, Jan IJmker, Stefan D. Anker, John G.F. Cleland, Hans L. Hillege, Chim C. Lang, Leong L. Ng, Nilesh J. Samani, Jasper Tromp, Dirk J. van Veldhuisen, Daan J. Touw, Adriaan A. Voors, Peter van der Meer
Journal: European Journal of Heart Failure (2019)
Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics.
Authors: Jayesh Mehta, A. Evens, O. Frankfurt, L. Gordon, D. Grinblatt, L. Kaminer, R. Meagher, M. Tallman, S. Williams, J. Winter, S. Singhal
Journal: Blood (2005)
Molecular Profiling of Extramedullary and Medullary Plasmacytomas Compared to Multiple Myeloma
Authors: Anuj Mahindra, Samir B. Amin, Aliyah R. Sohani, Gabriela Motyckova, Kishan Patel, Sonia Vallet, Samantha Pozzi, Loredana Santo, Diana Cirstea, Christiana E. Toomey, James S. Michaelson, Ephraim P. Hochberg, Paola Dal Cin, Scott J Rodig, Teru Hideshima, Kenneth C. Anderson, Nikhil C. Munshi, Noopur Raje
Journal: Blood (2010)
No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population
Authors: Luisa W Hugerth, Anna Andreasson, Nicholas J Talley, Anna M Forsberg, Lars Kjellström, Peter Thelin Schmidt, Lars Agreus, Lars Engstrand
Journal: Gut (2019)

Objective The ethiopathogenesis of irritable bowel syndrome (IBS) is unknown. While a link to the gut microbiome is postulated, the heterogeneity of the healthy gut makes it difficult to draw definitive conclusions. We aimed to describe the faecal and mucosa-associated microbiome (MAM) and health correlates on a community cohort of healthy and IBS individuals with no colonoscopic findings. Design The PopCol study recruited a random sample of 3556 adults; 745 underwent colonoscopy. IBS was defined by Rome IV criteria and organic disease excluded. 16S rRNA gene sequencing was conducted on sigmoid biopsy samples from 376 representative individuals (63 IBS cases) and faecal samples from 185 individuals (32 IBS cases). Results While sigmoid MAM was dominated by Lachnospiraceae, faeces presented a higher relative abundance of Ruminococcaceae. Microbial richness in MAM was linearly correlated to that in faeces from the same individual (R²=0.255, p&lt;3E-11) as was diversity (R²=0.06, p=0.0022). MAM diversity decreased with increasing body mass index (BMI; Pearson’s r=−0.1, p=0.08) and poorer self-rated health (r=−0.15, p=0.007), but no other health correlates. Faecal microbiome diversity was correlated to stool consistency (r=−0.16, p=0.043). Several taxonomic groups were correlated to age, BMI, depression and self-reported health, including Coprococcus catus associated with lower levels of depression (r=−0.003, p=0.00017). The degree of heterogeneity observed between IBS patients is higher than that observed between healthy individuals. Conclusions No distinct microbial signature was observed in IBS. Individuals presenting with low self-rated health or high BMI have lower gut microbiome richness.
Molecular Risk Stratification Predicts Engraftment Latency of Human Acute Myeloid Leukemia Cells Transplanted in NOD/SCID/IL-2Rgc-Null Mice
Authors: Anna M Paczulla, Stephan Dirnhofer, Martina Konantz, Michael Medinger, Helmut R. Salih, Kathrin Rothfelder, Jakob Passweg, Dimitrios Tsakiris, Pontus Lundberg, Claudia Lengerke
Journal: Blood (2016)
High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Has a Significant but Transient Impact on Quality of Life: Lessons From the Chronic Lymphocytic Leukemia (CLL) ASCT Study by the CLL Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Authors: Liesbeth C. de Wreede, Maggie Watson, Donald Milligan, Mauricette Michallet, Peter Dreger, Marleen van Os, Claire E. Dearden, Catherine Cordonnier, Michel Leporrier, Vladimir Koza, Janis Homewood, Bernadette Corront, Gabriela M. Baerlocher, Wolfgang Herr, Dietger Niederwieser, Laurent Sutton, Theo M. de Witte, Johannes Schetelig
Journal: Blood (2011)
Diffuse Low Grade Glioma - A 10-year single institution case series
Authors: Shami Acharya, Priya Sekhon, Jose Pedro Lavrador, Ravindran Visagan, Vijay Narbad, Josephine Jung, Richard Gullan, Francesco Vergani, Ranj Bhangoo, Keymours Ashkan
Journal: Neuro-Oncology (2019)

Abstract Objectives To study clinical features and treatment options between 2007–2018 in a population of diffuse low grade glioma (DLGG) patients (WHO Grade2). Methods Single centre retrospective cohort study. Variables reviewed: demographics, extent of resection (biopsy – Bx, subtotal resection – STR, gross total resection – GTR), molecular genetics and outcome. Results N=104.M=61 F=43, average age, 41.8 yrs. For their first surgery, 40.4% underwent a Bx, 32.7% STR, 26.9% GTR. 50.9% of patients had a second procedure due to clinical progression (13.8% Bx, 38.85% STR, 47.2% GTR). We were more surgically aggressive at the second sitting (p=0.0021). After 2014, we were more aggressive in terms of achieving a resection over a biopsy alone (pre 2013: 26 Bx, 24 resection, post 2013: 15 Bx, 28 resection). 35% had 1p19q co-deletion, 70% had 1DH1 mutation and 44.6% with MGMT methylated. There was no difference in survival and extent of resection in 1p19 co-deletions (HR 0.35), however there was in the IDH 1 group (HR 1.25. Post operatively, 37.9% patients had chemotherapy and 57.3 % radiotherapy. 80.5% (Bx 65,9% alive, resection 95% alive) of patients are still alive (longest survival 11.6 yrs). Amongst those who died, the mean overall survival was 4.0 (range 0–7 - 5 years): Of these 14% had undergone a Bx and 6% STR/GTR. The adjusted analysis revealed that EOR is the only revelant factor for survival in the population when adjusted for IDH, 1p19q, tumour volume, age, gender and surgery year (p=0.44). Conclusion Our data emphasises the importance of achieving maximal resection when possible.
A Phase I/II Study of Vaccination By Autologous Leukemic Apoptotic Corpse Pulsed Dendritic Cells for Elderly Acute Myeloid Leukemia Patients in First or Second Complete Remission (LAM DC trial)
Authors: Patrice Chevallier, Soraya Saiagh, Virginie Dehame, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Yannick Le Bris, Sylvain Bercegeay, Delphine Coulais, Marie-Aude Rambaud, Céline Bossard, Veronique Stocco, Brigitte Dreno, Nadine Juge-Morineau, Philippe Moreau, Marie-Christine Bene, Marc Gregoire
Journal: Blood (2016)
Therapy-Related PML-RARα Leukemia: An Emerging Disease. Report of 10 Cases From One Department of Hematology.
Authors: Maida Navarrete, Teresa Vallespi, Anny Jaramillo, Carmen Sánchez-Morata, Carlos Palacio, Noemí Martínez-Morgado, Ángel Guerra-Moreno, Margarita Ortega, Javier Bueno
Journal: Blood (2009)
Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma
Authors: Raija Silvennoinen, Muntasir Mamun Majumder, David Tamborero, Pekka Anttila, Samuli Eldfors, Riikka Karjalainen, Heikki Kuusanmäki, Juha Lievonen, Alun Parsons, Minna Suvela, Marjaana Säily, Kimmo Porkka, Caroline A Heckman
Journal: Blood (2014)
Small Molecule Inhibitor of Neutrophil Elastase Normalizes Myeloid Differentiation and Improves Impaired Cell Survival Triggered by Elastase Mutations In Patients with Severe Congenital Neutropenia and Acute Myeloid Leukemia
Authors: Andrew A. Aprikyan, Vahagn Makaryan, Maxim Totrov, Ruben Abagyan, David C. Dale
Journal: Blood (2010)
Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma,
Authors: Xiaolei Zhou, Jianmin Wang, Jessica Zhang, Catherine Copley-Merriman, Yasuhiro Torigoe, Carolina Reyes, John F. Seymour, Armando Lopez-Guillermo, Fritz C. Offner, Marek Trneny, Gilles Andre Salles
Journal: Blood (2011)
ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.
Authors: Paolo Neviani, Ramasamy Santhanam, Rossana Trotta, Mario Notari, Bradley W. Blaser, Ji-Suk Chang, Shujun Liu, Hsiaoyin Mao, Joshua J. Oaks, Denis C. Roy, Mauro Valtieri, Rebecca Bruner-Klisovic, Michael A. Caligiuri, Clara D. Bloomfield, Guido Marcucci, Danilo Perrotti
Journal: Blood (2005)